Johnson & Johnson (JNJ) Crosses $100 Billion As DePuy Synthes Buys Spine Tech

• Johnson & Johnson (NYSE:JNJ) has surpassed the $100b annual revenue mark for the first time in its 140 year history, supported by strong second quarter results.
• The company raised its guidance for 2026, signaling confidence in its longer term revenue outlook.
• MedTech unit DePuy Synthes agreed to acquire Expanding Innovations, Inc. to expand Johnson & Johnson’s presence in advanced spine surgery technology.

For investors watching Johnson & Johnson, the $100b revenue milestone arrives with a stock that is trading at $247.02 and has gained 19.1% year to date and 53.7% over the past year. The longer term picture is also strong, with the share price up 69.9% over three years and 67.8% over five years, reflecting how the market has treated the company’s scale in pharmaceuticals and MedTech.

These latest moves in MedTech, including the Expanding Innovations acquisition, add another layer to the Johnson & Johnson story for anyone tracking NYSE:JNJ as a healthcare anchor in a portfolio. The updated 2026 guidance and focus on advanced spine surgery technology may shape how investors think about the balance between its Innovative Medicine and MedTech operations over the coming years.

Stay updated on the most important news stories for Johnson & Johnson by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Johnson & Johnson.

📰 Beyond the headline: 1 risk and 3 things going right for Johnson & Johnson that every investor should see.

For Johnson & Johnson, crossing US$100b in annual revenue at the same time as DePuy Synthes moves to acquire Expanding Innovations signals how the MedTech side is being used to reinforce the broader healthcare platform. The second quarter numbers show sales at US$25.31b compared with US$23.74b a year earlier, while net income for the quarter was broadly flat and six month net income was lower than the prior period, so the revenue milestone is not simply about profit expansion. Instead, the raised 2026 sales guidance to a range of US$100.8b to US$101.4b and continued spending on areas like spine surgery technology and electrophysiology indicate a focus on product breadth and procedure-specific depth as Johnson & Johnson looks to compete with peers such as Medtronic, Abbott and Stryker in devices alongside Pfizer and Merck in medicines.

How This Fits Into The Johnson & Johnson Narrative

• The MedTech acquisition and FDA product approvals align with the narrative that Johnson & Johnson is using devices and surgery platforms to build additional earnings drivers alongside oncology and immunology therapies.
• The pressure on six month net income versus last year and ongoing talc litigation costs test the idea that investment, acquisitions and higher guidance automatically translate into smoother profit and margin expansion.
• The specific impact of spine focused deals and catheter platforms on long term surgery restructuring, and how they influence mix and profitability, is only partially reflected in the existing narrative and may need closer attention over time.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Johnson & Johnson to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Lower net income over the first six months of 2026 compared with the prior year shows that higher sales and guidance do not automatically translate into higher profitability.
• ⚠️ The affirmed US$45m talc verdict in Illinois and broader litigation around historical talc products underline that legal outcomes can still affect cash flows and capital allocation choices.
• 🎁 The raised 2026 sales outlook to more than US$100b and continued Q2 revenue growth point to ongoing demand across Johnson & Johnson’s Innovative Medicine and MedTech segments.
• 🎁 FDA approval of the Dual Energy THERMOCOOL SMARTTOUCH SF catheter and the Expanding Innovations acquisition give Johnson & Johnson more tools in high complexity procedure areas that competitors are also targeting.

What To Watch Going Forward

From here, it is worth tracking how Johnson & Johnson converts the higher revenue base and MedTech acquisitions into earnings, especially as guidance for 2026 sales sits just above the US$100b milestone. Watch commentary on MedTech margins, uptake of new platforms such as the dual energy catheter, and how spine technology from Expanding Innovations is integrated into DePuy Synthes. On the financial side, future quarters will give more clarity on whether net income trends start to move closer to the sales trajectory, how dividend decisions evolve from the current US$1.34 per share quarterly payout, and whether additional talc related rulings change the size or timing of legal cash outflows.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Johnson & Johnson, head to the community page for Johnson & Johnson to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com